Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;479(12):3229-3254.
doi: 10.1007/s11010-024-04933-1. Epub 2024 Feb 28.

Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy

Affiliations
Review

Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy

Lokesh K Kadian et al. Mol Cell Biochem. 2024 Dec.

Abstract

Cancer remains a major global health concern with high mortality rates mainly due to late diagnosis and poor prognosis. Long non-coding RNAs (lncRNAs) are emerging as key regulators of gene expression in human cancer, functioning through various mechanisms including as competing endogenous RNAs (ceRNAs) and indirectly regulating miRNA expression. LncRNAs have been found to have both oncogenic and tumor-suppressive roles in cancer, with the former promoting cancer cell proliferation, migration, invasion, and poor prognosis. Recent research has shown that lncRNAs are expressed in various immune cells and are involved in cancer cell immune escape and the modulation of the tumor microenvironment, thus highlighting their potential as targets for cancer immunotherapy. Targeting lncRNAs in cancer or immune cells could enhance the anti-tumor immune response and improve cancer immunotherapy outcomes. However, further research is required to fully understand the functional roles of lncRNAs in cancer and the immune system and their potential as targets for cancer immunotherapy. This review offers a comprehensive examination of the multifaceted roles of lncRNAs in human cancers, with a focus on their potential as targets for cancer immunotherapy. By exploring the intricate mechanisms underlying lncRNA-mediated regulation of cancer cell proliferation, invasion, and immune evasion, we provide insights into the diverse therapeutic applications of these molecules.

Keywords: Cancer; Cancer immunotherapy; Gene expression; LncRNA regulation; Long non-coding RNA; Treatment strategies.

PubMed Disclaimer

Similar articles

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI
    1. Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer 140:1955–1967 - PubMed - DOI
    1. Debela DT, Muzazu SG, Heraro KD et al (2021) New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med 9:205031212110343. https://doi.org/10.1177/20503121211034366 - DOI
    1. Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821. https://doi.org/10.1038/s41423-020-0488-6 - DOI - PubMed - PMC
    1. Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17:47–62 - PubMed - DOI

Substances

LinkOut - more resources